ResearchDevelopment and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials
ResearchTime to Treatment Initiation for the 30 Most Prevalent Cancer Types: Trends and Predictors of Change
ResearchDuration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
ResearchDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer — a systematic review and expert consensus
ResearchTranscriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial
ResearchPhase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)
ResearchTumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
ResearchIndividual income and race-associated differences in prostate cancer mortality in a statewide registry